SUMMARY The effect of a human fibrinogen preparation on in vitro platelet aggregation was assessed. Platelets were obtained from healthy volunteers. Human fibrinogen induced platelet aggregation in 65% of platelet rich plasma samples and enhanced submaximal platelet aggregation induced by heparin or by several conventional agonists in all samples. Aggregation induced by fibrinogen alone was reversed by the in vitro addition of human albumin. Fibrinogen induced aggregation was associated with the release of the vasoconstrictor, thromboxane A2. Preincubation with indomethacin inhibited both the aggregation and the release of thromboxane A2. Fibrinogen had no effect on in vitro vascular prostaglandin 12 synthesis (rat aortic rings) during a 60 minute incubation. The observed effects of fibrinogen on platelet function may be relevant to clinical conditions in which hyperaggregability of platelets is associated with hyperfibrinogenaemia and thrombosis.
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The association between increased plasma fibrinogen concentrations and an increased incidence of vascular disease is well documented.' -3 Increased plasma fibrinogen concentrations have been reported in patients with peripheral vascular disease,'-3 diabetes mellitus,'-3 Raynaud's syndrome, ' nephrotic syndrome,5 angina,6 myocardial infarction, '-3 6 7stroke,' -3 postsurgical trauma, ' 3 8 in smokers, ' -3 and in women taking oral contraceptives. ' -3 The converse also appears to be true: low plasma fibrinogen concentrations are associated with a diminshed risk of arterial disease, '-3 and preoperative partial defibrination results in a reduced incidence of postoperative venous thrombosis. ' 2 Epidemiological studies suggest that fibrinogen may even be a better predictor of coronary death than cholesterol. 3 It would, therefore, be of interest to explore, under controlled conditions, the potential mechanisms by which fibrinogen could enhance thrombogenesis. Several mechanisms have been considered, including the effect of fibrinogen on plasma viscosity, coagulation, and fibrinolysis. '-3 Fibrinogen also binds to platelets and is an essential requirement for platelet aggregation induced by cerAccepted for publication 6 June 1985 tain agonists.9 Platelet hyperactivity has also been reported in most of the conditions in which plasma fibrinogen concentrations are increased.'-3 10 11 Clinical trials have reported a highly significant correlation between plasma fibrinogen concentration and circulating platelet aggregates. ' 2 Furthermore, reduction of the fibrinogen concentration after the administration of ancrod resulted in a reduction in the number of circulating platelet aggregates. '2 In vitro studies, however, are conflicting. Some report that fibrinogen enhances platelet adhesion,' while others show that fibrinogen inhibits' or enhances' '4 platelet aggregation. To our knowledge, the induction of platelet aggregation in vitro by fibrinogen alone has not been reported. Finally, agents (including thromboxane A2) that induce aggregation expose platelet fibrinogen receptors, whereas inhibitors of aggregation (including prostacyclin) have the opposite effect. '5-7 The present study investigated certain aspects of the platelet-fibrinogen relation in vitro using a human fibrinogen preparation. Since the vascular endothelium produces prostacyclin (prostaglandin 12, a potent inhibitor of platelet aggregation, '8 The concentration of fibrinogen in platelet rich plasma (in the absence of added exogneous fibrinogen) was 1*9 to 2-2 g/l. These concentrations are lower than the expected normal value because of the added citrate, a requirement for the preparation of platelet rich plasma. It follows that, after the addition of 2 and 4 g/l of exogenous fibrinogen, the total concentration of fibrinogen in the platelet rich plasma ranged between 3-9-4-2 and 5-9-6 2 g/l. These small variations in fibrinogen concentration did not influence platelet function in our assay system. It was therefore unnecessary to make minor adjustments to the concentrations of exogenous fibrinogen, especially at the cost of delaying the platelet aggregation experiments, which depend on cell viability and therefore on the freshness of the sample.
As added safeguards, we (a) measured plasma fibrinogen concentrations (while aggregations were being carried out) to ensure that the values did not deviate from the range quoted above. Measurements were carried out using a Cobas Fibro (Roche Instruments, Welwyn Garden City, Herts, England); and (b) compared responses in platelet rich plasma samples with the lowest initial fibrinogen concentration (1.9 g/l) with those samples with the highest initial concentrations (2-2 g/l); there were no differences in the patterns of enhancement.
Aggregation was expressed as the percentage fall in optical density'920 and monitored for up to 15 minutes or until a maximum fall in optical density was sustained for one minute.
The platelet rich plasma from six subjects who reacted (more than 50% aggregation) to human fibrinogen (final concentration of added fibrinogen in the platelet rich plasma 4 g/l) was also assayed for thromboxane A2 generation, as previously described.2' Briefly, when maximal aggregation had occurred the platelet rich plasma (500 ul) was added to 1 ml ethanol (to stop the reaction) and vigorously mixed. The sample was then stored at -70°C until assay using a specific radioimmunoassay2' for thromboxane B2, the stable spontaneous breakdown product of thromboxane A2. Platelet counts in platelet rich plasma were measured using a Coulter Counter Model D (Coulter Electronics Limited, Luton, Beds, England) to allow the expression of throimboxane B2 results in terms of platelet count.2' Aggregation induced by fibrinogen in these six subjects was also repeated in platelet rich plasma that had been pre-incubated for one minute at 37°C with indomethacin (final concentration 8 mg/1) .22
The aggregation experiments with fibrinogen were repeated in four men and three women, with blood collected in 3-4% citrate instead of 3-8% citrate, in order to establish whether the citrate contained in the human fibrinogen preparation influenced the results.
All experiments were conducted with saline only (same volume as the fibrinogen-saline solution) added to platelet rich plasma to act as controls. Aggregations were always run in parallel, one aggregometer channel containing platelet rich plasma and fibrinogen and the other channel containing platelet rich plasma and saline (control).
Enhancement ofplatelet aggregation by fibrinogen Submaximal platelet aggregation was induced using low concentrations of adenosine diphosphate, adrenaline, serotonin, or collagen. Table 2 shows the final concentrations of these agonists. Eight subjects (five men, three women) were studied with each aggregating agent. The low concentrations of agonists were selected to produce submaximal aggregation and so allow the quantification of any enhancement of platelet aggregation after the addition of fibrinogen.2324
The potential enhancing effect of fibrinogen was also evaluated after the addition of heparin (Thromboliquine, Organon). The concentration of heparin selected (0.8-3 IU/ml) was always insufficient to cause more than 10% aggregation when added alone to platelet rich plasma.
Fibrinogen was added to platelet rich plasma in the aggregometer (final concentration of added fibrinogen 2 g/l). The amount of fibrinogen was selected so as not to cause substantial platelet aggregation (<10%) when added alone to platelet rich plasma from the same subject. After five minutes incubation, at 37°C in the aggregometer cuvette, the submaximal dose of the appropriate aggregating agent (or heparin) was added.
Controls consisted of the appropriate volumes of saline added in place of the fibrinogen-saline solutions. Aggregation was monitored until a maximal fall in optical density was sustained for one minute. Experiments were always run in parallel, one channel recording the platelet rich plasma plus saline plus submaximal dose of agonist (control experiment), the other platelet rich plasma plus fibrinogen plus submaximal dose of agonist.
In addition to the experiments described above, we also investigated whether fibrinogen induced enhancement of aggregation antagonises the Fibrinogen mediated activation ofplatelet aggregation and thromboxane A2 release three to 12 minutes). Control experiments consisted of appropriate volumes of saline added instead of the albumin solutions. Experiments were always run in parallel, one channel recording the platelet rich plasma plus albumin preparation plus fibrinogen, the other platelet rich plasma plus saline plus fibrinogen.
The effect of essentially fatty acid free and fraction V albumin, added in vitro, on platelet aggregation induced by conventional agents (adenosine diphosphate, adrenaline, collagen) was also assessed. Only the maximum concentrations of essentially fatty acid free albumin and fraction V albumin (6 g/l) used to abolish fibrinogen induced aggregation were evaluated. The concentration of agonists used (adenosine disphosphate 2-3 umolIl; adrenaline 2-5 ,molIl; collagen 0-2-1 mg/l) were selected so as to induce a percentage platelet aggregation similar to that induced by fibrinogen alone. Nine subjects (five men, four women) were evaluated.
Effect ofhuman fibrinogen on prostaglandin I2
release by rat aortic rings Since fibrinogen was found to enhance and even occasionally to intitiate platelet aggregation we investigated whether it also exerted any influence on prostaglandin I2 synthesis using rat aortic rings as a model. Rat aortic rings were prepared as previously described. 2'22 They were incubated in phosphate buffered saline (pH 7.4) at 37°C for 60 minutes in the absence and presence of fibrinogen (final concentFations 1, 2, 4, 8, and 16 gIl). The amount of 6-oxo-prostaglandin F,a (the stable spontaneous metabolite of prostacyclin, prostaglandin 12) released into the buffer during the 60 minutes incubation was quantified using a specific radioim- 21 22 munoassay. Table 1 , were tested in a few subjects and confirmed the same trend.
Fibrinogen induced release of thromboxane A2 in platelet rich plasma obtained from the six subjects who were selected because fibrinogen (final concentration of added fibrinogen in platelet rich plasma 4 g/l) had induced more than 50% aggregation. The median platelet thromboxane A2 release was 32, and the range was 15-60 ng of thromboxane B2/ml of platelet rich plasma or 10 (5-18) ng of thromboxane B2/108 platelets. Samples of platelet rich plasma, with saline only added, did not produce any substantial aggregation or thromboxane A2 release; in these samples of platelet rich plasma percentage aggregation was 4(0-10)% and thromboxane A2 release was <2 ng of thromboxane B2/ml of platelet rich plasma (<1 ng of thromboxane B2/108 platelets). Preincubation with indomethacin eliminated both the aggregation (to <10% aggregation) and the thromboxane A2 release (about 95% inhibited).
Collecting blood at lower citrate concentrations (3.4%) did not appreciably alter the results previously observed with fibrinogen and blood collected at the higher citrate concentration (3.8%). (TABLE 2) Fibrinogen consistently and appreciably enhanced submaximal platelet aggregation induced by several agonists (adenosine diphosphate, adrenaline, collagen, serotonin, heparin). Heparin alone was unable to induce platelet aggregation, but aggregation was observed when fibrinogen (final concentration 0*8-3-2 g/l) was also present. Exogenous fibrinogen antagonised prostaglandin 12 mediated inhibition of aggregation, the percentage aggregation always being greater in the samples of platelet rich plasma to which exogenous fibrinogen had been 1170 added than in the samples of platelet rich plasma with saline only. The fibrinogen degradation product assay (normal range in plasma <10 ,g/ml) detected <10 ,ug fibrinogen degradation product/ml of fibrinogen solution (final concentration of fibrinogen preparation 40 g/l). Heat precipitation of fibrinogen showed that the supernatant did not retain the ability to induce platelet aggregation. SDS gel electrophoresis showed the expected bands. Our findings clearly show that human fibrinogen cannot only enhance but also induce human platelet aggregation in platelet rich plasma. Other highly purified fibrinogen preparations'31" also enhance in vitro platelet aggregation induced by other agents under various experimental conditions. To our knowledge, however, platelet aggregation induced by the addition of fibrinogen alone has not been previously reported. In contrast, fibrinogen had no effect on vascular prostaglandin 12 release, but it did antagonise prostaglandin 12 mediated inhibition of in vitro platelet aggregation.
HUMAN FIBRINOGEN INDUCED ENHANCEMENT OF PLATELET AGGREGATION
The question remains whether our findings with human fibrinogen relate to pathological situations in vivo. Although this question cannot be conclusively answered, there is evidence that our in vitro findings are in accord with in vivo observations. The behaviour of human fibrinogen in the present study would go some way to explaining why plasma fibrinogen concentrations correlate with platelet aggregation26 and increased fibrinogen concentrations are associated with platelet aggregation and an increased incidence of vascular disease.27 Our results are also very similar to those showing that albumin, added in vitro, abolished spontaneous aggregation in samples obtained from patients with nephrotic syndrome." It is of interest that the concentrations of essentially fatty acid free human albumin required to neutralise aggregation in our experiments and the nephrotic syndrome study" are of a similar order. The mechanism involved in the abolition of aggregation by albumin is unclear but may relate, as previously suggested, to the ability of albumin to bind arachidonic acid, thromboxane A2, or endoperoxides." Such a view is compatible with the greater inhibitory potency of fatty acid free albumin than of fraction V albumin since the latter is rich in fatty acids.28 Our experimental observations would therefore predict that in the nephrotic syndrome, a condition where a low plasma albumin" and an increased plasma fibrinogen5 concentration are usually found, platelet hyperaggregability should occur. This is indeed the case; platelets have been shown to be hyperaggregable and to generate appreciably greater quantities of thromboxane A2.'0" An increased incidence of thrombotic events has also been reported in this condition. ' 
